niclosamide has been researched along with Carcinoma, Non-Small Cell Lung in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide is an antihe-minthic drug that has shown cytotoxic effects on non-small cell lung carcinoma (NSCLC) cells." | 1.56 | Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells ( Chai, WH; Chan, PC; Chao, YH; Chen, CH; Li, YR; Lin, CH; Lin, SH, 2020) |
| "Lung cancer is a leading cause of cancer-associated mortality worldwide." | 1.48 | Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc. ( Jiang, D; Li, H; Li, J; Xiang, M; Xu, Z; Yang, D; Yang, J; Yu, Y; Yu, Z; Zhou, H; Zuo, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erturk, E | 1 |
| Onur, OE | 1 |
| Aydin, I | 1 |
| Akgun, O | 1 |
| Coskun, D | 1 |
| Ari, F | 1 |
| Luo, F | 1 |
| Luo, M | 1 |
| Rong, QX | 1 |
| Zhang, H | 1 |
| Chen, Z | 1 |
| Wang, F | 1 |
| Zhao, HY | 1 |
| Fu, LW | 1 |
| Chai, WH | 1 |
| Li, YR | 1 |
| Lin, SH | 1 |
| Chao, YH | 1 |
| Chen, CH | 1 |
| Chan, PC | 1 |
| Lin, CH | 1 |
| Kim, MO | 1 |
| Choe, MH | 1 |
| Yoon, YN | 1 |
| Ahn, J | 1 |
| Yoo, M | 1 |
| Jung, KY | 1 |
| An, S | 1 |
| Hwang, SG | 1 |
| Oh, JS | 1 |
| Kim, JS | 1 |
| Zuo, Y | 1 |
| Yang, D | 1 |
| Yu, Y | 1 |
| Xiang, M | 1 |
| Li, H | 1 |
| Yang, J | 1 |
| Li, J | 1 |
| Jiang, D | 1 |
| Zhou, H | 1 |
| Xu, Z | 1 |
| Yu, Z | 1 |
| Yuquan, B | 1 |
| Hexiao, T | 1 |
| Laiyi, W | 1 |
| Gaofeng, P | 1 |
| Xuefeng, Z | 1 |
| Ming, X | 1 |
| Yanhong, W | 1 |
| Li, Z | 1 |
| Jinping, Z | 1 |
| Li, R | 1 |
| Hu, Z | 1 |
| Sun, SY | 1 |
| Chen, ZG | 1 |
| Owonikoko, TK | 1 |
| Sica, GL | 1 |
| Ramalingam, SS | 1 |
| Curran, WJ | 1 |
| Khuri, FR | 1 |
| Deng, X | 1 |
| Stewart, RL | 1 |
| Carpenter, BL | 1 |
| West, DS | 1 |
| Knifley, T | 1 |
| Liu, L | 1 |
| Wang, C | 1 |
| Weiss, HL | 1 |
| Gal, TS | 1 |
| Durbin, EB | 1 |
| Arnold, SM | 1 |
| O'Connor, KL | 1 |
| Chen, M | 1 |
8 other studies available for niclosamide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Targeting the epithelial-mesenchymal transition (EMT) pathway with combination of Wnt inhibitor and chalcone complexes in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Chalcone; Chalcones; Epithelial-Mes | 2023 |
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antinematodal Agents; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Smal | 2019 |
Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells
Topics: A549 Cells; Adenosine Triphosphate; Adenylate Kinase; Animals; Apoptosis; Autophagy; Carcinoma, Non- | 2020 |
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Topics: Anthelmintics; Antinematodal Agents; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2017 |
Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cisplatin; | 2018 |
Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Progression; ErbB | 2019 |
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Topics: Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplas | 2013 |
S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell | 2016 |